make posit adjust reiter neutral
market product solut
diagnost life scienc research market
requir disclosur end report
view current cl king meet event calendar coverag univers calendar
bio-rad post good beat revenu number although miss us
bit bottom line appear that littl aggress
cost-sav speed manag reiter guidanc base
view tough back half year comp thesi bio-rad
margin expans stori well-understood go-forward basi
compani need gener high end growth target rang
stock work view dont enough visibl
happen reiter neutral rate
thesi context quarter bio-rad chang non-
quarter follow revalu stake sartoriu
srt-f nr valu compani
valuat mani investor see quarter valuat realiz
period sartoriu held fair valu bio valuat
cosmet look better base non-gaap account
opinion alpha opportun alreadi price stock
number bio-rad post revenu
report foreign currenc neutral fxn vs
street compar quarter bio-rad
record revenu compani post ep
ye read correctli vs street
due mark-up ultra-low-bas sartoriu stake
adjust basi bio-rad post ep vs last year
guidanc bio-rad maintain fxn revenu growth
guidanc oper margin compani
note discontinu product sale
indirectli increas organ growth bp
reiter guidanc cfo christin tsingo also note non-
oper margin track
life scienc life scienc revenu
fxn vs came well ahead
estim note signific strength sale
droplet digit pcr cell biolog process media geograph
north america point strength februari bio-rad guid
fxn growth appear upsid
diagnost compani clinic diagnost revenu
fxn vs
basic line estim bio-rad cite diabet
immunolog qualiti control strong contributor februari
compani guid fxn growth bucket
diagnost note strength asia-pacif north
model modestli increas revenu estim
switch ep estim
adjust number adjust ep estim
adjust ep forecast base revenu
vs previou estim previou model use
report ep estim respect
meet manag later week follow
like fine-tun adjust ep estim
ddpcr singl cell life scienc segment remain fire
driven qx acquisit raindanc ad
revenu think meaning synergi even
intellectu properti ip legal perspect biggest concern
stock right overli optimist anticip meaning
contribut partnership ilmna
research suggest experienc challeng gain
traction singl cell market
abil cut cost
chang health care industry/regul
failur protect ip patent
lawsuit genom
lab consolid europ
page
